Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1998 March;42(1) > The Quarterly Journal of Nuclear Medicine 1998 March;42(1):54-65

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

ORIGINAL ARTICLES  BREAST CANCER II 

The Quarterly Journal of Nuclear Medicine 1998 March;42(1):54-65

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Nuclear medicine approaches for detection of axillary lymph node metastases

Bombardieri E., Crippa F., Maffioli L., Draisma A.**, Chiti A., Agresti R.*, Greco M.*

From the Division of Nuclear Medicine *Division Surgical Oncology B Istituto Nazionale Tumori, Milan, Italy **Department Radiology Leiden University Medical Center, Leiden, The Netherland


PDF


In ­breast can­cer ­patients the detec­tion of axil­lary ­lymph ­node involve­ment is a ­very crit­i­cal ­issue, in ­view of the ear­li­er diag­no­sis of the dis­ease in ­recent ­years, and the ­increased fre­quen­cy of ­very ­small ­tumors at ­first pres­en­ta­tion. The ­size of can­cer is relat­ed to the ­risk of axil­lary metas­ta­ses, and ­this may ­affect the prog­no­sis and the ther­a­peu­tic strat­e­gies. Axillary ­lymph ­node involve­ment is gen­er­al­ly rec­og­nized as an ­index of dis­tant micro­dif­fu­sion, and as it ­affects over­all and dis­ease-­free sur­vi­val, rep­re­sents the ­basis for adop­tion of adju­vant chem­o­ther­a­py. Routine axil­lary ­lymph ­node dis­sec­tion (­ALND) is expen­sive, and ­does not ben­e­fit ­about 70% of ear­ly ­breast can­cer ­patients ­which are ­node neg­a­tive (pN-). Today most of ­these ­patients ­have to sus­tain the poten­tial mor­bid­ity and the eco­nom­ic ­costs of ­ALND. The clin­i­cal ­approach is ­known to be an unre­al­i­able diag­nos­tic ­tool, and for the detec­tion of axil­lary metas­ta­ses, con­ven­tion­al X-ray tech­niques are ­also ­unable to ­solve the prob­lem. By con­trast, nucle­ar med­i­cine pro­ce­dures ­have ­revealed a ­very inter­est­ing diag­nos­tic poten­tial in ­recent ­years. This ­paper ana­lyz­es the numer­ous stud­ies con­duct­ed in the ­field of ­lymph ­node vis­u­al­iza­tion and the het­ero­ge­ne­ity of the pub­lished expe­ri­enc­es, tak­ing ­into ­account the dif­fer­ent approach­es pro­posed in the lit­er­a­ture: a) imag­ing ­with gam­ma-emit­ting ­tumor seek­ing ­agents; b) radio­im­mu­nos­cin­tig­ra­phy ­intra-­venous (i.v.) or by the inter­sti­tial ­route; c) lym­phos­cin­tig­ra­phy ­with col­loids and gam­ma ­probe sen­ti­nel biop­sy; d) posi­tron emis­sion tomog­ra­phy (PET). Although it is ­very dif­fi­cult to ­make a defin­i­tive state­ment ­about the clin­i­cal effi­ca­cy of all ­these meth­ods, ­this ­paper ­reports the ­most impor­tant ­series of ­patients exam­ined in the li-t­er­a­ture as ­well as the ­author’s own expe­ri­enc­es. This can ­serve as the ­basis for a bet­ter under­stand­ing of the poten­tial of nucle­ar med­i­cine pro­ce­dures, and ­gives the read­er the oppor­tu­nity to ­weigh advan­tag­es and draw­backs of ­each meth­od. At ­present, lym­phos­cin­tig­ra­phy ­with gam­ma ­probe sen­ti­nel biop­sy and FDG-PET ­are the nucle­ar med­i­cine approach­es ­with the ­best diag­nos­tic per­for­mance. However, a cor­rect com­par­i­son of the meth­ods ­will not be pos­sible, ­until ­their care­ful assess­ment in the ­same ­patients is performed. In addi­tion, a ­final state­ment ­today ­should con­sid­er ­also the increas­ing ­need to car­ry out an eco­nom­ic anal­y­sis by eval­u­at­ing the ­cost-effec­tive­ness of the exam­ina­tions.

inizio pagina